PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy

Several clinical studies demonstrate that there exist other immune checkpoints overexpressed in some PD-1 inhibitor-resistant tumor patients. Among them, Lymphocyte-activation gene 3 (LAG-3) is one of the important immune checkpoint molecules and has been clinically demonstrated to have synergistic...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Ning Shi, Yangyihua Zhou, Yujun Liu, Ran Zhang, Xingjun Jiang, Caiping Ren, Xiang Gao, Longlong Luo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Subjects:	immune checkpoint PD-1 LAG-3 bispecific antibody cancer immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1047610/full